supplementary table 1
DESCRIPTION
Supplementary table 1. Supplementary table 2. Supplementary table 3. A. B. Supplementary table 4. Supplementary table 5. Supplementary table 6. A. B. C. Supplementary Fig. S1. A. B. miR-155. c ontrol. siTRF1. miR-155. c ontrol. siTRF1. -. -. +. +. MG132. -. -. +. +. - PowerPoint PPT PresentationTRANSCRIPT
Supplementary table 1
Supplementary table 2
Supplementary table 3
Supplementary table 4
A.
B.
VALIDATED hsa-miR-155 TARGETSAGTR1AICDABCL2
CSF1RCTLA4CUX1ETS1FGF7IKBKE
IL13RA1INPP5DIRAK3JARID2MYD88RIPK1
RNF123SKISLA
SOCS1SPI1
WEE1
Supplementary table 5
Supplementary table 6
Supplementary Fig. S1
A. B. C.
Flag-TRF1
actin
MG132
siTRF
1
- + +-control miR-155
1.00 2.55 1.13 2.05
2mgWB a-TRF1
MG132 siTRF
1
- + +-control miR-155
Flag-TRF1 end. TRF1
actin
20mgWB a-TRF1
1.00 1.38 0.52 0.71 0.18end. TRF1/actin
*
B.
C.
A.
con. miRNA
mir-155
antag
o-miR-155
con. siRNA
siTRF1
0
20
40
60
80
100
120
TRF1
mRN
A le
vels
norm
alize
d to
acti
n (c
on.m
iRN
A se
t “1”
)
n=3n=3
n=3
n=3
n=3
p=0.3p=0.2 p=0.012
Supplementary Fig. S2
Flag-TRF1/actin
Supplementary Fig. S3
miR-155 signature low: n=593
miR-155 signature high: n=606
ER positive tumors
Supplementary Fig. S4
B.A.
miR
-155
a-m
iR-1
55
cont
rol
6000
5000
4000
3000
2000
1000
0
7000
8000
TRF1
fluo
resc
ence
inte
nsity
(a.f.
u)
1312±30.52n=602N=41
1051±31.08n=512N= 40
1464±37.79 n=508 N= 31
p<0.0001
p<0.0001
cont
rol
miR
-155
anta
go-
miR
-155
TRF1 TRF1/DAPI
anta
go-
miR
-155
MBA
-MD-
468
U 2-
OS
D.C.
miR
-155
a-m
iR-1
55
cont
rol
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
POT1
fluo
resc
ence
inte
nsity
(a.f.
u)
1199±101.7n=1199N=35
p=0.119
p=0.071
1552±86.24
n=1552 N= 37
985±101.4n=985N= 30
cont
rol
miR
-155
anta
go-
miR
-155
POT1 POT1/DAPI
5000
1000
10000
miR
-155
a-m
iR-1
55
cont
rol
TRF2
fluo
resc
ence
inte
nsity
(a.f.
u)
150001619
±54.45n=1173N=48
p=0.4
p=0.065
1584±41.40
n=1267N= 48
1694±51.07n=1050N= 48
cont
rol
miR
-155
anta
go-
miR
-155
TRF2 TRF2/DAPI
TRF2
mRN
A le
vels
norm
alize
d ve
rsus
acti
n
con-trol
miR-155
0
0.5
1
1.5
2
2.5
3
n=3 n=3
p=0.2
con-trol
miR-155
0
0.5
1
1.5
2
2.5
3
TRF1
mRN
A le
vels
norm
alize
d ve
rsus
acti
n
n=3n=3
p=0.2
con-trol
miR-155
0
10
20
30
40
50
60
70
80
miR
-155
leve
lsno
rmal
ized
vers
us R
NU4
6
n=3
n=3
p<0.0001
cont
rol
miR
-155
con-trol
mir-155
0
20
40
60
80
100
120
TRF1
pro
tein
leve
lsno
rmal
ized
vers
us a
ctin n=3
n=3
p=0.01
A. B.
D.C.
E.
TRF1
actin
Supplementary Fig. S5
telo
mer
e le
ngth
(a.f.
u.)
A
B
C
1591± 30.72
N=42n=3823
1916± 37.47N=39
n=3521
p<0,0001
2000
10000
12000
14000
16000
4000
6000
8000
0
cont
rol
miR
-155
cont
rol
miR
-155
0
20
40
60
80
100 > 4000 1500-40000-1500A
BC
telo
mer
e a.
f.u in
tesis
ty c
ateg
orie
s (%
)
cont
rol
miR
-155
0
10
20
30
40
50
60
p=0.035
N=3n=50
N=3n=50
TIF
freq
uenc
y(2
< TI
Fs; %
)
0
25
50
75
100
125
150
miR
-155
leve
ls, n
orm
lized
to R
NU4
6 (c
on se
t “1”
)
cont
rol
miR
-155
cont
rol
miR
-155
TRF1actin
cont
rol
siTRF
1
01020304050607080
TIF
frequ
ency
3< T
IFs;
%)
p=0.05
N=3n=81
N=3n=93
Supplementary Fig. S6
A.
B. C. D.
cont
rol
siTR
F1
05
10152025303540
n=1370
n=1533N=17
N=20
p= 0,03
fragi
le te
lom
eres
(%)
Supplementary Fig. S7
A.
cont
rol
miR
-155
05
10152025303540
N=40n=3084
N=40n=3098
p=0,003
fragi
le te
lom
eres
(%)
B.
C. D.
0102030405060
Chart Title
N=25n=1974
N=25n=1906
p= 0,04
fragi
le te
lom
eres
(%)
-+
--+
+ Aphidicolin
con.miRNA
antago-miR-155 antago-miR-155
0
2
4
6
8
10
-+
--
+
+ Aphidicolin
con.miRNA
p=0.05
N=26n=2134
N=21N=1542
telo
mer
ic si
ster
ch
rom
atid
fusio
ns (%
)